key: cord-0257051-e6c7uml9
authors: Goodall, B. L.; LeBlanc, J. J.; Hatchette, T. F.; Barrett, L.; Patriquin, G.
title: Investigating sensitivity of nasal or throat (ISNOT): A combination of both swabs increases sensitivity of SARS-CoV-2 rapid antigen tests
date: 2022-01-21
journal: nan
DOI: 10.1101/2022.01.18.22269426
sha: d15688b8c0e2cf0baee92889d28d5208f038acb4
doc_id: 257051
cord_uid: e6c7uml9

The COVID-19 pandemic has been hallmarked by several waves of variants of concern (VoCs), each with novel challenges. Currently, the highly transmissible Omicron VOC is predominant worldwide, and sore throat is common among other cold-like symptoms. Anecdotes on social media suggested sampling ones throat can increase sensitivity for Omicron detection by antigen-based rapid testing devices (Ag-RDTs). This work determines whether the sensitivity of Ag-RDTs designed for nasal sampling is altered with use of self-administered throat swabs in self-perceived asymptomatic individuals. This investigation compared results of a common Ag-RDT (i.e. Abbott Panbio COVID-19 Ag Rapid Test Device) using three sampling sites: nasal swab; throat swab and; combined nasal/throat. All Ag-RDT results were confirmed with molecular testing. Compared to RT-PCR, samples from nasal or throat swabs each detected 64.5% of SARS-CoV-2 cases; however, combining the contributions of each swab increased sensitivity to 88.7%. This trend was also evident with the Rapid Response Ag-RDT (BTNX), which uses a more flexible swabs than Panbio. When nasal swab collection was compared to paired sampling of the nasal/throat using a single swab with the Panbio Ag-RDT, the sensitivity of each was 68.4% and 81.6%, respectively. No false-positive results were observed with nasal, throat, or combined nasal/throat sampling. Self-administered throat and nasal/throat swabs both had >90% acceptability. These findings support the use of self-collected combined nasal/throat sampling for Ag-RDT based SARS-CoV-2 detection in self perceived asymptomatic individuals.

The COVID-19 pandemic is an ongoing threat to global public health. Since the first cases were reported 44 in December 2019, several SARS-CoV-2 variants concern (VoCs) have emerged, causing multiple waves of 45 infection globally 1 . In the last 4 weeks, the predominant VoC in many jurisdictions is SARS-CoV-2 lineage 46 B.1.1.529, designated Omicron by the World Health Organization (WHO) classification working group 1 , 47 which is highly mutated, with over 50 mutations compared to ancestral reference genomes 2,3 . Most 48 mutations are present in the gene encoding spike, the protein that is targeted by all current vaccines, and 49 plays a role in host receptors interactions to facilitate viral entry and subsequent replication. Among other 50

Omicron mutations, four mutations are in the gene encoding nucleocapsid, the target of most antigen-51 based rapid diagnostic tests (Ag-RDTs). While some recent data have alleviated initial concerns over the 52 possibility of decreased sensitivity of Ag-RDTs with Omicron, there are other noted differences from 53 previous VOCs 4 . Omicron has increased transmission, reduced vaccine effectiveness 5,6 , and recent studies 54 results 15 . Misunderstanding erroneous test results can fuel misinformation and disinformation, ultimately 66 undermining confidence in public health efforts and trust in healthcare professionals. 67

At a low barrier volunteer-led community testing centre 16 , whereby samples were self-collected with 68 coaching, this work sought: to investigate whether Omicron could be detected with Ag-RDTs in 69 asymptomatic individuals; to evaluate the potential benefits of throat sampling; and assess the 70 applicability of throat sampling to other Ag-RDTs using different swabs. 71 72 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.18.22269426 doi: medRxiv preprint antigen detections and to investigate the possibility of false negative results 16 . Briefly, the remaining fluid 97 in the Ag-RDT tubes along with the used swabs for all participants (Ag-RDT positive or negative) were 98 transported to a central laboratory, and 200 µl of viral transport medial (VTM) (Rodoxica, Little Rock AR) 99 was added to each tube. Following gentle vortexing for 5 seconds, the VTM/fluid was transferred to a 100 microcentrifuge tube, and 150 µl was subjected to a total nucleic acid (TNA) extraction on a MaNAPure 101 LC 2.0 instrument (Roche Diagnostics ltd., Roltkreuz, Switzerland), according to manufacturer instructions. 102

TNAs were eluted in a volume of 50 µl and 5 µl was used as template in a real-time RT-PCR using the 103 TaqPath CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.18.22269426 doi: medRxiv preprint A global crisis such as a pandemic and the rapid dissemination of information through social media can 154 fuel perpetuation of anecdotes, misinformation, and disinformation that can hamper public health efforts 155 and trust in healthcare professionals. This quality project assessed assertions from media (social, print, 156 televised), urging the public to swab their throat in addition to (or instead of) their nares for testing with 157

Ag-RDTs. In this project, a combined collection of both nasal and throat samples increased Ag-RDT 158 sensitivity compared to the manufacturer recommended sampling of bilateral nares alone. To our 159 knowledge, this is the first report of the self-collected Ag-RDT performance of Ag-RDTs for Omicron 160 detection in an asymptomatic population. 161

Given the propensity of cold-like symptoms and complaints of sore throat during this period of high 162 prevalence of Omicron, there was likely some validity to the media accounts of false-negative nares swabs, 163 with subsequent follow-up positive throat swabs. Many of the Ag-RDTs available to the public are based 164 on nasal swabs, and are not approved for sampling saliva or the throat and previous work shows the 165 potential for invalid results when using an assay outside of the manufacturer's instructions 15 . Without 166 careful evaluation of this widely publicized phenomenon, variables such as test timing (and time between 167 nasal and throat tests), testing kit manufacturer, swab types, and buffers, cannot be controlled. 168

Importantly, confirmation of test results with more sensitive and specific assays (such as RT-PCR) cannot 169 be easily performed to corroborate individual anecdotes. Investigations in this work allowed for careful 170 evaluation of SARS-CoV-2 detection using Ag-RDTs, using nasal and throat swabs.

potentially impact the performance of Ag-RDTs or of molecular testing 17 , all of the Ag-RDT-positive throat 174 samples in this project were confirmed as positive by RT-PCR. Based on our experience with community-175 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.18.22269426 doi: medRxiv preprint individuals, which is consistent with manufacturer claims. Given the widespread activity of Omicron in the 177 community, it was not surprising that few false positives were observed. 178

Apart from ensuring Ag-RDT specificity with use of a throat-based collection, understanding its potential 179 impacts on sensitivity is also crucial. The sensitivity of the Ag-RDT for Omicron detection was 82% (versus 180 RT-PCR) when using the combined nasal and throat swabs, which is on the higher end of estimates is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.18.22269426 doi: medRxiv preprint respectively) 8 which was opposite from the performance reported for previously circulating variants. 201

Similarly, in a pre-print non-peer reviewed publication of a small subset of individuals in a high-risk 202 occupational case cohort, the viral load in saliva specimens peaked 1 to 2 days prior to those observed 203 with nasal swab collections 23 . These early data suggest there may be a different tissue tropism for the 204

Omicron variant compared to prior circulating lineages of SARS-CoV-2 7 . 205

Most individuals being tested agreed to participate, with only approximately 6% refusing, indicating that 206 a self-administered throat swab is an acceptable method for COVID-19 testing. Tolerability of throat 207 swabs and of combined nasal/throat swabs appeared to be high, without voiced concerns for swab 208 preference. Participants often performed the self-administered throat swab correctly with minimal 209 coaching. Many participants experienced a gag reflex during the self-administered throat swab, and one 210 individual vomited. This in-person volunteer observation and coaching could easily be translated to a 211 brief instructional video for at-home/occupational use. 212

This investigation is not without limitations. Our adult population is from a single centre during a seven-213 day period, at a community testing centre. There was no collection of clinical information related to 214 patient demographics, timing from exposure, immunization history, or recent consumption of food or 215 drink. One of the criteria for attending the testing site was self-described asymptomatic status. However, 216 mild symptoms may not have been recognized as Omicron infection. Practically speaking, swabbing both 217 nasal and throat using a single swab can be done without regard for timing of symptoms or exposure, and 218 should increase rates of detection using Ag-RDTs. This is particularly important as self-directed testing and 219 management become a tool of endemic living, these data add confidence to the ability of individuals to 220 adequately perform reliable sample collection in a real-world setting. 221

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.18.22269426 doi: medRxiv preprint BTNX Rapid Response suggest that this enhanced detection rate using a combined swab is applicable to 223 other lateral flow tests, although further studies are warranted. While molecular confirmation with RT-224 PCR was available, RTB is not a typical testing matrix. Despite our previous validations of RTB for this 225 application 16 , this approach is not as sensitive as an independent collection of swabs for RT-PCR testing 226 using dedicated transport media. As such, the sensitivity of Ag-RDTs may be overestimated in this project, 227 but this would apply to each swab type. However, not all real-world settings with vaccinated individuals 228 still aim to identify the presence of molecular viral genetic material. The use of RT-PCR in this case was to Overall, this work provides early evidence that combined throat and bilateral nasal swabs maximize the 242 ability of Ag-RDTs to identify the Omicron variant. These types of projects are instrumental in testing 243 anecdotal reports to inform the community practice and increase confidence for those making swabbing 244 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 21, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 21, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 21, 2022. ; https://doi.org/10.1101/2022.01.18.22269426 doi: medRxiv preprint

World Health Organization. Tracking SARS-CoV-2 variants